The trial was intended to test the safety and toxicity of CV9201, besides its ability to induce antigen-specific humoral and cellular immune responses in cancer patients.
The trial with CV9201, tested an immunotherapy based on CureVac´s RNActive vaccination technology in patients after heavy pre-treatment with chemotherapy and 65% of the phase IIa study patients responded to at least one antigen out of the five antigens in CV9201.
The study evaluated a five dose regime of CV9201 delivered via intradermal injection in 46 patients and found that CV9201 is safe, well tolerated and biologically active.